The long term goal of this project is to elucidate the role of aldehyde dehydrogenases (ALDH3A1 and ALDH1A1) in the ocular defense mechanism against ultraviolet radiation (UVR) toxicity. It is well known that UVR induces reactive oxygen species (ROS) that leads to membrane lipid peroxidation and accumulation of toxic aldehydes, such as 4-hydroxy-2- nonenal (4-HNE). Both ALDH3A1 and ALDH1A1 detoxify 4-HNE, which has been implicated in the pathogenesis of several diseases including cataract and degenerative retinal disease. During the last funding period, we have made novel and significant discoveries regarding the protective role of ALDH3A1 and ALDH1A1 against ocular oxidative stress. We found that both enzymes protect against UVR- and 4-HNE-induced cellular toxicity, and that, at least ALDH3A1, may act as UVR filter protecting other enzymes from inactivation. Finally, and most importantly, we found that Aldh3a1(-/-) and Aldh1a1(-/- )/Aldh3a1(-/-) knockout mice develop anterior and posterior subcapsular cataracts early in life, whereas Aldh1a1(-/-) knockout animals develop cataracts later in life. These novel data support our working hypothesis that corneal ALDH3A1 and lens ALDH1A1 protect the eye against cataract formation via non-enzymatic (light filtering) and enzymatic (detoxification) functions. The experiments proposed in this competitive renewal application continue our systematic approach to characterizing the role of corneal ALDH3A1 and lens ALDH1A1 in the protection against UVR- induced eye pathologies. In the next 5 years, we propose to:
Specific Aim 1 : To distinguish the physiological functions of non-enzymatic (light filtering) from enzymatic (detoxification) functions of ALDH3A1 and ALDH1A1 by developing Aldh3a1 and Aldh1a1 knock-in mouse lines that express enzymatically- inactive proteins. The ocular phenotypes of these knock-in mouse models will be compared to that of the Aldh3a1(-/-) and Aldh1a1(-/-) knockout mice and wild-type animals Specific Aim 2: Examine the hypothesis that novel and selective small molecule activators of ALDH1A1 and ALDH3A1 will protect the eye against UVR-induced pathologies. Following administration of these activators and exposure to UVR, corneal injury and cataract formation will be studied in parallel with formation and characterization of 4-HNE-adducted proteins in wild-type and Aldh-knockout mice.
Specific Aim 3 : Evaluate the hypothesis that ALDH3A1 and ALDH1A1 protect the retina. The protective effects of both ALDH3A1 and ALDH1A1 will be determined by identifying aging- and UVR-induced biochemical and histological changes in the retina of Aldh3a1(-/-), Aldh1a1(-/-) and Aldh3a1(-/-)/Aldh1a1(-/-) single and double knockout mouse lines. These studies will provide valuable data on (a) the role and the molecular mechanisms of the ocular ALDH1A1 and ALDH3A1 in protecting the eye from UVR-induced oxidative damage and (b) drug development that may be used to prevent eye pathologies. It is anticipated that the information gleaned from these studies will lead to novel approaches for the prevention and treatment of eye diseases in the human population.
of this research to public health: It is well documented that ultraviolet radiation (UVR) causes eye pathologies in cornea, lens and retina. Opacification of the lens, known as cataract, is the leading cause of blindness in the world. Cornea and lens contain some proteins, namely aldehyde dehydrogenases (ALDH1A1 and ALDH3A1), that protect against UVR-induced cataract formation and corneal pathologies. The proposed research will characterize the role and the molecular mechanisms of ocular ALDH1A1 and ALDH3A1 in protecting the eye from UVR-induced damage, and will serve as a foundation for future drug development.
|Monte, Andrew A; Heard, Kennon J; Hoppe, Jason A et al. (2015) The accuracy of self-reported drug ingestion histories in emergency department patients. J Clin Pharmacol 55:33-8|
|Monte, Andrew A; Heard, Kennon J; Campbell, Jenny et al. (2014) The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness. Acad Emerg Med 21:879-85|
|Chen, Ying; Thompson, David C; Koppaka, Vindhya et al. (2013) Ocular aldehyde dehydrogenases: protection against ultraviolet damage and maintenance of transparency for vision. Prog Retin Eye Res 33:28-39|
|Brocker, Chad; Vasiliou, Melpomene; Carpenter, Sarah et al. (2013) Aldehyde dehydrogenase (ALDH) superfamily in plants: gene nomenclature and comparative genomics. Planta 237:189-210|
|Vasiliou, Vasilis; Sandoval, Monica; Backos, Donald S et al. (2013) ALDH16A1 is a novel non-catalytic enzyme that may be involved in the etiology of gout via protein-protein interactions with HPRT1. Chem Biol Interact 202:22-31|
|Singh, Surendra; Brocker, Chad; Koppaka, Vindhya et al. (2013) Aldehyde dehydrogenases in cellular responses to oxidative/electrophilic stress. Free Radic Biol Med 56:89-101|
|Bchini, Raphael; Vasiliou, Vasilis; Branlant, Guy et al. (2013) Retinoic acid biosynthesis catalyzed by retinal dehydrogenases relies on a rate-limiting conformational transition associated with substrate recognition. Chem Biol Interact 202:78-84|
|Jackson, Brian C; Holmes, Roger S; Backos, Donald S et al. (2013) Comparative genomics, molecular evolution and computational modeling of ALDH1B1 and ALDH2. Chem Biol Interact 202:11-21|
|Chen, Ying; Johansson, Elisabet; Yang, Yi et al. (2010) Oral N-acetylcysteine rescues lethality of hepatocyte-specific Gclc-knockout mice, providing a model for hepatic cirrhosis. J Hepatol 53:1085-94|
|Scharer, Gunter; Brocker, Chad; Vasiliou, Vasilis et al. (2010) The genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy due to mutations in ALDH7A1. J Inherit Metab Dis 33:571-81|
Showing the most recent 10 out of 18 publications